Literature DB >> 27315247

A case of fatal Guillain-Barre syndrome from anti-PD1 monoclonal antibody use.

Aasems Jacob1, Dileep C Unnikrishnan2, Aju Mathew3, Braghadheeswar Thyagarajan2, Shil Patel2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27315247     DOI： 10.1007/s00432-016-2191-7

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN： 0171-5216            Impact factor:   4.553


× No keyword cloud information.
  5 in total

Review 1.  Guillain-Barré syndrome.

Authors:  Nobuhiro Yuki; Hans-Peter Hartung
Journal:  N Engl J Med       Date:  2012-06-14       Impact factor: 91.245

2.  Anti-CTLA-4 antibody-induced Guillain-Barré syndrome in a melanoma patient.

Authors:  S Wilgenhof; B Neyns
Journal:  Ann Oncol       Date:  2011-02-28       Impact factor: 32.976

3.  Increased circulating T cell reactivity to GM1 ganglioside in patients with Guillain-Barré syndrome.

Authors:  Peter A Csurhes; Alice-Ann Sullivan; Kerryn Green; Judith M Greer; Michael P Pender; Pamela A McCombe
Journal:  J Clin Neurosci       Date:  2005-05       Impact factor: 1.961

Review 4.  Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies.

Authors:  J Naidoo; D B Page; B T Li; L C Connell; K Schindler; M E Lacouture; M A Postow; J D Wolchok
Journal:  Ann Oncol       Date:  2015-09-14       Impact factor: 32.976

5.  A severe case of ipilimumab-induced guillain-barré syndrome revealed by an occlusive enteric neuropathy: a differential diagnosis for ipilimumab-induced colitis.

Authors:  Caroline Gaudy-Marqueste; Sandrine Monestier; Jérome Franques; Emmanuel Cantais; Marie-Aleth Richard; Jean-Jacques Grob
Journal:  J Immunother       Date:  2013-01       Impact factor: 4.456
  5 in total
  10 in total

1.  Guillain-Barré syndrome in patients treated with immune checkpoint inhibitors.

Authors:  Qianqian Fan; Yang Hu; Xiang Wang; Bin Zhao
Journal:  J Neurol       Date:  2021-01-21       Impact factor: 4.849

2.  Polymyalgia rheumatica in a melanoma patient due to nivolumab treatment.

Authors:  Kiyotaka Nakamagoe; Tetuya Moriyama; Hiroshi Maruyama; Masahiro Yokosawa; Tadashi Hara; Shinya Tanaka; Manabu Fujimoto; Akira Tamaoka
Journal:  J Cancer Res Clin Oncol       Date:  2017-05-17       Impact factor: 4.553

Review 3.  Immune Checkpoint PD-1/PD-L1: Is There Life Beyond Antibodies?

Authors:  Markella Konstantinidou; Tryfon Zarganes-Tzitzikas; Katarzyna Magiera-Mularz; Tad A Holak; Alexander Dömling
Journal:  Angew Chem Int Ed Engl       Date:  2018-02-23       Impact factor: 15.336

Review 4.  Neurologic Immune-Related Adverse Events Associated with Immune Checkpoint Inhibition.

Authors:  Peter Chei-Way Pan; Aya Haggiagi
Journal:  Curr Oncol Rep       Date:  2019-11-27       Impact factor: 5.075

Review 5.  Neuromuscular Complications of Programmed Cell Death-1 (PD-1) Inhibitors.

Authors:  Justin C Kao; Adipong Brickshawana; Teerin Liewluck
Journal:  Curr Neurol Neurosci Rep       Date:  2018-08-04       Impact factor: 5.081

6.  Progressive multifocal leukoencephalopathy after durvalumab treatment for acute myeloid leukemia: A consequence of an immune reconstitution inflammatory syndrome?

Authors:  Emeline Vinatier; Caroline Poli; Aurélien Giltat; Christopher Nunes-Gomes; Corentin Orvain; Mathilde Hunault-Berger; Pascale Jeannin; Sylvain Thépot
Journal:  EJHaem       Date:  2022-05-29

Review 7.  Coexisting myasthenia gravis, myositis, and polyneuropathy induced by ipilimumab and nivolumab in a patient with non-small-cell lung cancer: A case report and literature review.

Authors:  Jia-Hung Chen; Kang-Yun Lee; Chaur-Jong Hu; Chen-Chih Chung
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817

8.  Safe Transition to Pembrolizumab following Ipilimumab-Induced Guillain-Barré Syndrome: A Case Report and Review of the Literature.

Authors:  Nicholas Gravbrot; Katalin Scherer; Srinath Sundararajan
Journal:  Case Rep Oncol Med       Date:  2019-11-22

9.  Durvalumab-Induced Demyelinating Lesions in a Patient With Extensive-Stage Small-Cell Lung Cancer: A Case Report.

Authors:  Wenhui Liu; Bo Chen; Yiping Liu; Zhiying Luo; Bao Sun; Fang Ma
Journal:  Front Pharmacol       Date:  2022-01-03       Impact factor: 5.810

Review 10.  Immune Checkpoint Inhibitors and Neurotoxicity.

Authors:  Zhiyi Zhao; Chunlin Zhang; Lian Zhou; Pan Dong; Lei Shi
Journal:  Curr Neuropharmacol       Date:  2021       Impact factor: 7.363
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.